DCDarren R. Cullinan

Darren R. Cullinan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Darren R. Cullinan has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Declining allocation out of sequence is associated with fewer kidneys recovered and transplanted

    by Shin Lin, Aaron M. Delman, Gregory R. Martens, Gary F. Marklin, Thomas Levanos, Samuel Z. Grinberg, Natnael B. Doilicho, Jennifer Yu, Yikyung Park, Neeta Vachharajani, et al.

  • Open Access

    Robotic hepatectomy across IWATE difficulty levels: a single-center experience of the first 100 cases

    by Diego F. Chaparro-Zaraza, Jessica Lindemann, Amen Z. Kiani, Angela L. Hill, Neeta Vachharajani, Caleb Harsin, Darren R. Cullinan, William C. Chapman, Maria B. Majella-Doyle, Adeel S. Khan

    This study describes our institutional experience with robotic hepatectomy, analyzes trends, and evaluates intraoperative and postoperative outcomes stratified by IWATE-defined procedural difficulty. Retrospective cohort study of the first 100 consecutive robotic hepatectomies performed by the abdominal transplant division at a high-volume center (2017–2025). Outcomes were compared across IWATE groups and between early (2017–2021) and late (2022–2025) cohorts. Logistic regression was used to examine the association between IWATE score and conversion to open surgery, 30-day complications, and major complications (Clavien–Dindo ≥ IIIa). Median age was 61 years (IQR 47–70), 52% were female, and 77% had malignant disease. 28% of resections were major. IWATE categories were low in 29%, intermediate 46%, advanced 7%, and expert 18%. Median operative time was 217 min (IQR 160–294), estimated blood loss was 150 mL (IQR 50–300), and length of stay was 3 days (IQR 2–4). Conversion to open surgery occurred in 22% with no emergent cases; 30-day complications occurred in 21%, major complications in 10%, readmission in 5% and 90-day mortality in 1%. Over time, expert cases and major hepatectomies increased without statistically significant differences in conversion or complication rates. Across IWATE groups, operative time, Pringle use, blood loss, transfusion, conversion, and length of stay increased with complexity ( p < 0.001). Each 1-point increase in IWATE score independently increased the odds of conversion (adjusted OR 1.45, 95% CI 1.12–1.88) but not overall or major complications. Robotic hepatectomy was feasible across IWATE-defined difficulty levels while maintaining good perioperative outcomes. Increasing IWATE difficulty was associated with greater intraoperative complexity and a significantly higher likelihood of conversion to open surgery, although it was not independently associated with increased postoperative morbidity.


  • Open Access

    Awareness and Perceptions of Flexibility in Surgical Training: Insights From a National Survey of Surgical Fellowship Program Directors

    by Steven Tohmasi, Judith C. French, Darren R. Cullinan, Ariana Naaseh, Katharine E. Caldwell, Michael M. Awad, John A. Olson, Mary E. Klingensmith, Paul E. Wise


  • Open Access

    Supplementary Data from Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer

    by Hui Peng, C. Alston James, Darren R. Cullinan, Graham D. Hogg, Jacqueline L. Mudd, Chong Zuo, Rony Takchi, Katharine E. Caldwell, Jingxia Liu, David G. DeNardo, et al.

    Supplementary tables and figures

  • Open Access

    Data from Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer

    by Hui Peng, C. Alston James, Darren R. Cullinan, Graham D. Hogg, Jacqueline L. Mudd, Chong Zuo, Rony Takchi, Katharine E. Caldwell, Jingxia Liu, David G. DeNardo, et al.

    Purpose:FOLFIRINOX has demonstrated promising results for patients with pancreatic ductal adenocarcinoma (PDAC). Chemotherapy-induced immunogenic cell death can prime antitumor immune responses. We therefore performed high-dimensional profiling of immune cell subsets in peripheral blood to evaluate the impact of FOLFIRINOX on the immune system.Experimental Design:Peripheral blood mononuclear cells (PBMC) were obtained from treatment-naïve (n = 20) and FOLFIRINOX-treated patients (n = 19) with primary PDAC tumors at the time of resection. PBMCs were characterized by 36 markers using mass cytometry by time of flight (CyTOF).Results:Compared with treatment-naïve patients, FOLFIRINOX-treated patients showed distinct immune profiles, including significantly decreased inflammatory monocytes and regulatory T cells (Treg), increased Th1 cells, and decreased Th2 cells. Notably, both monocytes and Treg expressed high levels of immune suppression-associated CD39, and the total CD39+ cell population was significantly lower in FOLFIRINOX-treated patients compared with untreated patients. Cellular alterations observed in responders to FOLFIRINOX included a significantly decreased frequency of Treg, an increased frequency of total CD8 T cells, and an increased frequency of CD27−Tbet+ effector/effector memory subsets of CD4 and CD8 T cells.Conclusions:Our study reveals that neoadjuvant chemotherapy with FOLFIRINOX enhances effector T cells and downregulates suppressor cells. These data indicate that FOLFIRINOX neoadjuvant therapy may improve immune therapy and clinical outcome in patients with PDAC.

  • Open Access

    FIGURE 4 from In Silico Epitope Prediction Analyses Highlight the Potential for Distracting Antigen Immunodominance with Allogeneic Cancer Vaccines

    by C. Alston James, Peter Ronning, Darren Cullinan, Kelsy C. Cotto, Erica K. Barnell, Katie M. Campbell, Zachary L. Skidmore, Dominic E. Sanford, S. Peter Goedegebuure, William E. Gillanders, et al.

    Shared neoantigen analysis in common allogeneic vaccine cancer types. A, Lysate-based overlap analysis. Counts of shared neoantigens per patient for each cancer type based on a lysate-based vaccine administration are shown on the left. Counts summarize 10 complete trial simulations (300 simulated patients total) for each cancer type. A heatmap of shared neoantigen identities from combined trials in each cancer type (300 simulated patients) is shown on the right. B, Cell-based overlap analysis. Counts of shared neoantigens per patient for each cancer type based on cell-based vaccine administration are shown on the left. Counts summarize 10 complete trial simulations (300 simulated patients) for each cancer type are shown on the left. A heatmap of shared neoantigen identities from combined trials in each cancer type (300 simulated patients) is shown on the right.

  • Open Access

    Supplementary Data from In Silico Epitope Prediction Analyses Highlight the Potential for Distracting Antigen Immunodominance with Allogeneic Cancer Vaccines

    by C. Alston James, Peter Ronning, Darren Cullinan, Kelsy C. Cotto, Erica K. Barnell, Katie M. Campbell, Zachary L. Skidmore, Dominic E. Sanford, S. Peter Goedegebuure, William E. Gillanders, et al.

  • Open Access

    FIGURE 3 from In Silico Epitope Prediction Analyses Highlight the Potential for Distracting Antigen Immunodominance with Allogeneic Cancer Vaccines

    by C. Alston James, Peter Ronning, Darren Cullinan, Kelsy C. Cotto, Erica K. Barnell, Katie M. Campbell, Zachary L. Skidmore, Dominic E. Sanford, S. Peter Goedegebuure, William E. Gillanders, et al.

    Shared neoantigen analysis in melanoma. A, Single Iteration of a simulated clinical trial using TCGA's melanoma (SKCM) cohort. The count of each patient's (n = 30) protein-altering somatic variants and predicted neoantigens are shown in the top left panel. Quantification of each designated “vaccine” sample, both individually (n = 3) and as a pooled “Vaccine” are provided in the top right panel. Shared variants and predicted neoantigens by cell-based and lysate-based analysis are shown in the bottom panel. B, Lysate-based neoantigen analysis of melanoma simulated clinical trial. Ten clinical trials in melanoma were simulated analyzing a total of 300 patients. The total number of shared neoantigens that each patient shared with the vaccine, by lysate-based analysis, is shown in the left. In patients who had one or more shared neoantigens with the vaccine, the identity and frequency of each neoantigen is shown in the right. C, Cell-based neoantigen analysis of melanoma simulated clinical trial. Ten clinical trials in melanoma were simulated analyzing a total of 300 patients. The total number of shared neoantigens that each patient shared with the vaccine, by cell-based analysis, is shown in the left. In patients who had one or more shared neoantigens with the vaccine, the identity and frequency of each neoantigen is shown in the right.

  • Open Access

    FIGURE 1 from In Silico Epitope Prediction Analyses Highlight the Potential for Distracting Antigen Immunodominance with Allogeneic Cancer Vaccines

    by C. Alston James, Peter Ronning, Darren Cullinan, Kelsy C. Cotto, Erica K. Barnell, Katie M. Campbell, Zachary L. Skidmore, Dominic E. Sanford, S. Peter Goedegebuure, William E. Gillanders, et al.

    Simulated clinical trial work flow and shared neoantigen analysis. Using cancer-type matched cohorts from the TCGA, 33 samples were selected randomly and designated as either “vaccine” (n = 3) or “patient” (n = 30). Analysis was then performed to determine the number of shared tumor-specific neoantigens between the pooled vaccine and each patient individually. Right, a neoantigen analysis workflow is depicted. Tumor-specific neoantigens were determined for each sample individually in the following order. All somatic variants in the tumor were first identified. Non–protein-altering variants were excluded. The total pool of possible peptides was then calculated, and those that did not result in a predicted neoantigen with an IC50 < 500 nm were excluded for the lysate-based analysis. In addition, predicted neoantigens not presented on both the vaccine and patient's MHC haplotype were excluded for the cell-based analysis (Materials and Methods).

  • Open Access

    FIGURE 2 from In Silico Epitope Prediction Analyses Highlight the Potential for Distracting Antigen Immunodominance with Allogeneic Cancer Vaccines

    by C. Alston James, Peter Ronning, Darren Cullinan, Kelsy C. Cotto, Erica K. Barnell, Katie M. Campbell, Zachary L. Skidmore, Dominic E. Sanford, S. Peter Goedegebuure, William E. Gillanders, et al.

    TAA expression analysis. A, TAA expression in a single simulation of a pancreatic adenocarcinoma clinical trial. Tumor associated antigen counts (MUC1 and Mesothelin for PAAD) are summarized for an example trial simulation in pancreatic adenocarcinoma. TAAs were assessed for each patient after taking into account the MHC alleles for either patient only (lysate-based analysis) or patient and vaccine (cell-based analysis), requiring evidence for both presentation of TAA peptide and robust expression of the TAA gene (Methods). B, TAA expression in each of five cancer types. For each cancer type, select established TAA genes were considered (Gp100, Ny-ESO-1 and MART-1 for SKCM; VEGFR1 and Ny-ESO-1 for LUAD; VEGFR1 and Ny-ESO-1 for LUSC; PSA and PAP for PRAD). Counts of expressed TAAs across 300 patients for each tumor type are shown as violin plots with individual points representing the count for each simulated patient overlaid.